Biotricity Achieves Market Expansion in Two New States
REDWOOD CITY, Calif., March 27, 2019 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, has expanded its sales team to cover two additional states in the US that are key to driving faster adoption of its flagship product, Bioflux. The Company has been experiencing great traction with its technology in the marketplace and is taking the opportunity to capitalize on its momentum and increase its regional footprint. Biotricity is confident that broadening its influence through expansion in high growth sectors will help accelerate sales, drive revenue, and develop market share.
"Our Bioflux was met with a high adoption rate in the clinical community throughout our soft launch over the past year," said Casey Shattuck, Biotricity Global VP of Sales. "From a sales perspective, I have tremendous confidence in our expansion based on the overwhelmingly positive customer feedback we've received and our re-order rates thus far."
The Company's remote patient monitoring device Bioflux monitors a patient's ECG in near real-time, constantly analyzing and collecting data on the device and periodically uploading to the cloud via embedded cellular technology.
"Our expansion comes on the heels of great reception in other states," said Mr. Waqaas Al-Siddiq, Biotricity Founder and CEO. "We have secured loyal anchor clients in key industry markets with great customer feedback. This has bolstered our confidence and we believe we are well placed to grow and to kick off the next phase of the Company."
Biotricity is growing its presence in the connected-health market; an estimated 36 million patients are expected to be equipped with remote monitoring devices by 2020. With Bioflux, Biotricity believes doctors will have unprecedented levels of relevancy and timeliness to patient ECG information.
